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A B S T R A C T
The oral cavity is of great importance to the performance of orally retained formulations, including: orally
disintegrating tablets, taste-masked formulations, and buccal/sublingual delivery systems. With regards to in
vitro dissolution assessment of these dosage forms, human saliva should be represented by the dissolution media.
Currently there is no general consensus regarding oral cavity dissolution. In this study pooled human saliva was
characterised and utilised as dissolution media for biorelevant oral cavity dissolution studies and to assess drug
release. Lipophilic drug felodipine with challenging biopharmaceutical properties was selected for assessment in
oral cavity dissolution studies. These saliva dissolution studies investigated for the first time how biorelevant
dissolution can be implemented as a screening tool to guide the formulation development process and to predict
dosage form performance within the mouth. In this study a combination of three dissolution enhancement
strategies (cryomilling, solid dispersion, and inclusion complexation) were employed to eventually increase the
concentration of felodipine in saliva 150-fold. Using this successful formulation strategy orally disintegrating
tablets of felodipine were produced. Interestingly, the percentage release of felodipine in compendial dissolution
apparatus was shown to be over 80% after 10min. On the other hand, saliva-based dissolution showed that
percentage release of felodipine was only 0.2% after 10min using the same formulation. This discrepancy in
drug release between dissolution media highlights the need for biorelevant dissolution apparatus for the oral
cavity to reliably assess performance of relevant dosage forms in vitro.
1. Introduction
The oral cavity is a site for drug dissolution that is generally over-
looked in pharmaceutical development. Following the oral adminis-
tration of drugs there are several processes which take place over a
relatively short period of time. These processes include: disintegration,
dissolution, taste perception, drug absorption, and drug removal via
swallowing. Compared to conventional solid oral dosage forms, such as
tablets and capsules, orally retained formulations can be greatly im-
pacted by the time spent within the oral cavity. The performance of
orally retained formulations such as sublingual and buccal tablets, or-
ally disintegrating tablets (ODTs), and oral films in the oral cavity rely
on disintegration and dissolution in saliva (Bartlett and van der Voort
Maarschalk, 2012). On the other hand, there are orally retained
formulations that aim to prevent disintegration and dissolution within
saliva as a method of taste-masking. Therefore, a robust method of
determining dissolution of dosage forms and drug release in saliva is
important.
In development of orally retained formulations numerous tests can
be used to assess the performance of the dosage form in the oral cavity,
including: wetting time, disintegration, moisture uptake, and dissolu-
tion tests. With regards to dissolution testing, current approaches used
for orally retained formulations are usually the same as the methods
used for conventional tablets. The dissolution of conventional tablets is
typically done with United States Pharmacopeia (USP) apparatuses 1–4
(Azarmi et al., 2007; Kraemer et al., 2012). Typical dissolution media
used in USP dissolution include: 0.1M HCl, buffers at pH from 1.2 to
7.5, simulated gastric/intestinal fluid, water, and surfactant solutions.
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The conventional dissolution procedures, such as USP apparatuses,
were not initially designed to be biorelevant for the oral cavity (Gittings
et al., 2014). Therefore, these compendial dissolution methods might
not accurately reflect how a formulation will perform within the oral
cavity. Therefore, dissolution method conditions different from the
current conventional procedures will be required for biorelevant eva-
luation of drug performance within the oral cavity (Hermans et al.,
2017).
There have been several dissolution tests that have aimed for bior-
elevant dissolution of the oral cavity (Yajima et al., 2002; Hoang Thi
et al., 2012; Tietz et al., 2018). However, there is no general consensus
on what parameters should be used in oral cavity dissolution (Gittings
et al., 2014). What is agreed, is that a biorelevant dissolution testing
would be of great value and would allow for a robust assessment
method with better predictions of in vivo behaviour and dosage form
performance (Dressman and Reppas, 2000; Kostewicz et al., 2002;
Okumu et al., 2008; Shono et al., 2009; Sunesen et al., 2005; Vertzoni
et al., 2005; Hermans et al., 2017). However, currently available
methods have limited biorelevance. Current approaches for oral cavity
dissolution testing have not yet formed a clear basis on what the dis-
solution media should be used as a surrogate for human saliva. Several
different approaches have been taken to simulate saliva for use in
pharmaceutical development (Gal et al., 2001; Guhmann et al., 2012).
In addition, there have been reports in the fields of oral hygiene and
food sciences of using of actual human whole saliva as dissolution
media (Saxegaard et al., 1988; Buettner, 2002; Manarelli et al., 2017).
To use human saliva in a reliable and reproducible manner for purposes
of dissolution, pooling methods were previously employed to reduce
inter-individual variability (Schipper et al., 2007). In addition, for a
better prediction of the formulation performance in the oral cavity,
dissolution media volumes were adjusted to realistic volume to better
reflect resident volume of saliva in the mouth (Lagerlof and Dawes,
1984; Rudney et al., 1995). In this study, dissolution exposure time was
set to 10min to be used as a formulation screening trade-off time end
point for various orally retained formulations, such as ODTs and taste-
masked formulations. While this exposure time is longer than the
average disintegration time of ODTs (European Pharmacopeia, 2014;
United States Pharmacopeia, 2014), it is shorter than the time required
to prevent dissolution for effective taste masking (Lopez et al., 2018).
Saliva is composed of 99% water, therefore compounds with poor
aqueous solubility will require dissolution enhancement strategies for
successful ODT development. There are various techniques available for
increasing drug solubility and therefore dissolution (Savjani et al.,
2012; Sharma and Baldi, 2016; Bavishi and Borkhataria, 2016; Al-
kassas et al., 2017; Khames 2017; Repka et al., 2018). The solubility
enhancing techniques used in this study included: particle size reduc-
tion, solid dispersions, and inclusion complexes. Firstly, cryomilling
was used to enhance dissolution by reducing particle size and by
creating amorphous drug particles. Then a polymeric solubilizer, So-
luplus® was used to aid the solubilisation of poorly soluble drugs in
aqueous media and to stabilise the amorphous milled drug material.
Lastly, complexation with cyclodextrins was used as it can improve the
aqueous solubility of lipophilic compounds.
ODTs have been shown to be attractive dosage forms due to their
ease of use for the patient. Another benefit to dosage forms fated for
dissolving or disintegrating in the oral cavity is that it allows for direct
absorption through the oral mucosa allowing drugs to reach systemic
circulation bypassing the gastrointestinal tract and hepatic first-pass
metabolism. For some compounds, the ability to decrease irritation to
the subsequent compartments of the gastrointestinal tract can be ad-
vantageous, for example, piroxicam can be used in an ODT formulation
to avoid its side effect of gastric irritation (Lai et al., 2011). ODTs have
also shown potential when rapid onset of drug action is required, for
example, headache relief and freedom from pain with rizatriptan ODTs
(Cameron et al., 2015). There have been a number of lipophilic com-
pounds that have been formulated as ODTs for commercial use, such as:
loratadine, ondansetron, tepoxalin, loperamide, and cisapride (Fu et al.,
2004). In the present study felodipine was used as a model lipophilic
compound to assess the suitability of biorelevant human saliva dis-
solution as a screening tool to guide the development and optimisation
of an ODT formulation.
Felodipine is a 1,4-dihydropyridine derivative that acts as a calcium
antagonist and is primarily used in the treatment of angina pectoris and
hypertension. Felodipine is a lipophilic, crystalline powder with very
low water solubility of around 3 µg/mL (Kim et al., 2006; Mielcarek
et al., 2006). According to the Biopharmaceutics Classification System
(BCS), felodipine is a class II drug, as it has low aqueous solubility and
high permeability. The oral bioavailability of felodipine is low (15%)
mostly due to poor aqueous solubility and extensive first-pass meta-
bolism both in the intestinal wall and the liver (Dunselman and Edgar,
1991). In addition, patients with hypertensive crisis and angina some-
times require drugs with quick onset of action. Therefore, formulating
felodipine as an ODT could be advantageous to achieve more rapid
onset of action, and buccal absorption could avoid first pass metabolism
effects. There have been previous reports of formulating felodipine as
an ODT (Basalious et al., 2013; Tung et al., 2014), however, previous in
vitro dissolution testing for felodipine ODTs used USP 2 methods as
described by the U.S. Pharmacopeia monograph (United States
Pharmacopeia, 2009). This USP 2 approach has very limited similarity
to the oral cavity, therefore it is unlikely to give a useful indication of
ODT performance in the mouth.
Therefore, the aim of the present work was to use pooled human
stimulated saliva in dissolution as a screening tool to guide the devel-
opment and optimisation of ODT formulation of a model lipophilic
compound, felodipine.
2. Materials and methods
Felodipine API powder was kindly donated by AstraZeneca
(Macclesfield, UK), Soluplus® and Kollidon CL (polyvinylpyrrolidone,
crosslinked) by Baden Aniline and Soda Factory (BASF) company
(Germany) and spray dried lactose by Foremost Farms (USA).
Magnesium stearate, sodium dodecyl sulphate (SDS), methyl-beta-cy-
clodextrin (MβCD) and beta-cyclodextrin (βCD) were purchased from
Sigma Aldrich (Gillingham, UK), and colloidal silicon dioxide 2% was
purchased from JRS (Germany). Methyl-tert-butyl ether (MTBE) was
purchased from Fisher Scientific (UK). All solvents used in the study
were HPLC grade or higher.
2.1. Collection of human saliva from healthy adult volunteers
All human saliva samples were collected in accordance with Ethics
Reference Number: R12122013 from Faculty of Medicine and Health
Sciences, Nottingham University Hospitals. Participation was voluntary
and informed written consent was obtained. All data was held in ac-
cordance with the Data Protection Act. Exclusion criteria included
chronic or acute illness in the past 3months, cold or flu symptoms, oral
health concerns, and taking medication (except contraceptives).
Participants were asked to not eat, smoke, drink or use oral hygiene at
least 2 h before collection of saliva. To avoid differences in saliva due to
circadian rhythms, all saliva was collected between 14:00 and 16:00 h.
Participants first donated unstimulated (US) saliva before being
asked to chew on 5 cm×5 cm square of Parafilm® for stimulated (SS)
saliva, which is a known inert material that is widely used for me-
chanical stimulation of saliva (Aiuchi et al., 2008; Bardow et al., 2000;
Christersson et al., 2000; Inoue et al., 2008). To donate saliva, parti-
cipants were asked to lean forward and drain saliva into sterile poly-
propylene graduated centrifuge tubes via sterile disposable funnels
(Grenier Bio-One, UK). Saliva samples were then flash frozen in liquid
nitrogen and stored at −80 °C. In total, four volunteers donated un-
stimulated and stimulated saliva (demographic data are shown in
Appendix A. Supplementary Data). The donated saliva was pooled,
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characterised, and used in dissolution studies.
2.2. Characterisation of pooled human saliva
Pooled saliva was characterised for: pH, buffer capacity, viscosity,
and surface tension. An S220 seven compact pH/ion meter was used
with InLab Science Pro electrode (Mettler Toledo, Switzerland) to
measure pH. For buffer capacity each pooled saliva sample (4mL) was
preheated to 37 °C. The sample was titrated with 0.01M HCl at 37 °C
until pH had decreased by 1 unit. The buffer capacity in mmol H+/L
was calculated by measuring the volume of acid added. An Anton Paar
Modular Compact Rheometer (MCR) 302 (Anton Paar GmbH,
Germany) was used with a cone-plate set up to measure viscosity. The
cone was a CP50-2-SN30270, diameter 49.972mm, angle 2.016°,
truncation 211 µm. Viscosity measurements were taken at 37 °C, over
three logarithmic decades for shear rate from 1 to 1000 s−1 with
measurements taken at 8 points per decade. Data was recorded on
Rheoplus software (Anton Paar GmbH, Germany) for analysis. A DSA
100 Drop Shape Analyser using a pendant drop method with DSA 4
software (Kruss GmbH, Germany) was used to measure surface tension.
Temperature was set to 37 °C using an MB-5 heat circulator and water
bath (Julabo GmbH, Germany).
2.3. Oral cavity dissolution studies of felodipine and its formulations in
pooled stimulated human saliva
The volume of saliva used in this oral cavity dissolution method was
based on mimicking the resident saliva volume within the adult human
mouth (Lagerlof and Dawes, 1984; Rudney et al., 1995). Multiple glass
tubes (16×100mm) were used as dissolution vessels and were kept at
37 °C each with a magnetic stirrer. One mL of pooled stimulated human
saliva was added to 2.5mg felodipine, as depicted in Fig. 1. After the
addition of saliva to the drug, dissolution run time was set to 10min
with constant 200 rpm stirring speed to allow adequate mixing of solid
material in relatively small volumes of media, and for direct compar-
isons between different formulations. As the dissolution procedure in
this study aimed to rapidly screen and rank-order multiple formula-
tions, a single time point was used. At the 10-minute time point the
whole dissolution sample was directly transferred to Costar Spin-X
centrifuge tubes with 0.22 µm pore cellulose acetate (CA) filters
(Corning Life Sciences, UK) and centrifuged for 5min at 17,000×g.
The following formulations components were tested as powders in
human saliva dissolution: felodipine API powder (as received), cryo-
milled felodipine, co-cryomilled felodipine and Soluplus®, cryomilled
felodipine complexed with βCD or MβCD, co-cryomilled felodipine and
Soluplus® complexed with βCD or MβCD.
The following formulations were tested as ODTs in human saliva
dissolution: felodipine API powder (as received), co-cryomilled felodi-
pine and Soluplus®, co-cryomilled felodipine and Soluplus® complexed
with MβCD.
2.4. Compendial dissolution studies of felodipine formulations in USP 2
apparatus
Compendial dissolution was performed using USP 2 apparatus
(Erweka Dissolution Tester, Germany) with phosphate buffer at pH 6.5
containing 1% SDS, as recommended by the felodipine monograph
designed for extended release tablets (United States Pharmacopeia,
2009). The volume of media used was 600mL, and was maintained at
37 °C. A paddle speed of 50 rpm was employed. For comparisons to be
made to oral cavity dissolution, at 10min 5mL samples were with-
drawn, and underwent the same sample preparation steps used for
saliva dissolution samples. The ODTs containing co-cryomilled felodi-
pine and Soluplus® complexed with MβCD were assessed.
2.5. Determination of felodipine in pooled stimulated saliva by HPLC-UV
Hundred μL of the saliva sample was transferred to a glass test tube,
along with: 10 μL of internal standard (IS), and 300 μL of acetonitrile
(stored at −20 °C), then vortex mixed for 2min. Next, 200 μL of water
was added to each tube, and vortex mixed for a further 2min. Then,
4mL of methyl-tert-butyl ether (MTBE) was added to each test tube,
vortex mixed at 1200min−1 for 10min in a multi-tube vortexer (VWR
VX-2500), and then centrifuged at 1690×g for 10min. Following
centrifugation, the organic layer was transferred and evaporated to
dryness under nitrogen. The dry residue was then reconstituted with
100 μL of mobile phase (60% ACN, 40% water). Reconstituted samples
were then vortex mixed and centrifuged, before transferring the con-
tents to HPLC vials. All calibration and quality control samples under-
went the same sample preparation procedures as stated for the dis-
solution samples.
A Waters (Milford, USA) 2695 separations module HPLC system and
Waters 996 diode array UV detector was used. Samples in the auto-
sampler were maintained at 4 °C and the column oven was set to 50 °C.
Empower 2 software was used for data processing.
Separation of the extracted felodipine sample was achieved with
Supleco LC-18 4.6×150mm, 5 μm particle size column, with Xterra
MS C18 2.1×10mm 3.5 μm guard column and pre-column filter in-
cluding a 0.5 μm stainless steel frit. Mobile phase was 60% ACN and
40% HPLC grade water, eluted at isocratic conditions at 0.6mL/min.
Cannabidiol was used as the internal standard (IS). Felodipine and
cannabidiol were detected at 360 nm and 220 nm at 7.4 and 15.4min
respectively. The accuracy and precision of the method gave acceptable
values of± 15% relative error (RE), and ≤15% relative standard de-
viation (RSD) respectively from both intra-day and inter-day analyses
(US Food and Drug administration (FDA), 2001). The lowest limit of
quantification (LLOQ) for felodipine (lowest determined concentration
of felodipine in spiked pooled saliva samples that had acceptable ac-
curacy and precision of RE ± 20%, and RSD≤20% respectively) was
determined to be 25 ng/mL in both saliva states. Calibration curves
were constructed in the concentration ranges expected from dissolution
of the drug in saliva. Calibration curves all had correlation coefficient
(r2) values of> 0.99. The recovery of felodipine from pooled stimu-
lated saliva dissolution samples was 100.10 ± 0.56% (mean ± SD,
n=3).
2.6. Cryomilling of felodipine and co-milling with Soluplus®
Cryomilling was performed on felodipine and Soluplus® using a
6870 Freezer/Mill (SPEX, USA) as described previously (Hameed,
2017). One gram of total weight of either felodipine API alone, Solu-
plus® alone or their mixture (1:1 ratio) was subjected to cryomilling for
150min. The starting material was pre-cooled for 3min and then milled
for 2min. The material was then cooled and milled on a cycle until
150min was reached. Cryomilled material was then vacuum sealed in
an argon filled environment with relative humidity of 7% to minimise
as far as possible moisture uptake. Production of amorphous material
Fig. 1. A schematic representation of the oral cavity dissolution set up utilising
human saliva as dissolution medium. Pooled human saliva (1mL) was added to
2.5mg of felodipine and stirred at 200 rpm for 10min. At the 10-minute time
point the whole sample was taken for sample preparation and analysis via
HPLC-UV.
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was confirmed by X-ray powder diffraction (XRPD) as described in
Appendix A. Supplementary Data.
2.7. Preparation of felodipine mixtures and complexation with
cyclodextrins
A physical mixture of cryomilled felodipine with cryomilled
Soluplus® was mixed thoroughly in the dry state at 1:1 ratio. The
mixture was then passed through a No. 60 sieve and stored in a de-
siccator. Complexation with cyclodextrins was undertaken with two
methods; kneading and lyophilisation. The kneading method was used
with MβCD and βCD, cyclodextrins were placed into a mortar, mois-
tened with 50% ethanol and kneaded to a paste consistency. Felodipine
was then added at equimolar ratios to cyclodextrins and kneaded into
the mixture whilst adding successively 50% ethanol. The kneaded
mixtures were then dried at 50 °C for 8 h. The dried powder was then
passed through a No. 60 sieve and stored in a desiccator.
For the lyophilisation method both MβCD and βCD was used to
make 50mL of respective cyclodextrin solutions in water, then
felodipine was added and stirred at 500 rpm to form a stable suspen-
sion. Methanol was then added to the solution at room temperature and
was stirred for 12 h. Then the solution was flash frozen in liquid ni-
trogen and lyophilised in a Scanvac CoolSafe Touch 110-4 freeze dryer
(Labogene, Denmark) to give a solid complex. Freeze-dried samples
were ground in a mortar, then passed through a No. 60 sieve and stored
in a desiccator.
2.8. Production of felodipine orally disintegrating tablets (ODTs)
Blends containing cryomilled felodipine and cryomilled Soluplus®
(1:1) were mixed with excipients to give 0.8% drug loading resulting in
2.5 mg felodipine in a 300mg tablet (8 mm diameter, 5 mm height).
The following excipients were added to the formulations to give a
300mg tablet: Kollidon CL (15mg), spray dried lactose (271mg), col-
loidal silicon dioxide (6mg), magnesium stearate (3mg). 60 g batches
were produced in a blender. The tablets were then compressed using
concave punches on the Piccola multi-station press (Riva SA, Argentina)
using 8mm flat, round tooling at 6 kN compression force.
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Fig. 2. Characterisation of pooled human saliva samples. (a) pH of pooled unstimulated and stimulated human saliva (n= 12, triplicate). Box represents median
value, 25th and 75th percentile. Whiskers represent maximum and minimum values. (b) Buffer capacity of pooled unstimulated and stimulated human saliva (n= 4,
triplicate). Box represents median value, 25th and 75th percentile. Whiskers represent maximum and minimum values. (c) Viscosity of pooled unstimulated and
stimulated human saliva (n= 3, duplicate), at different shear rates. (d) Surface tension of pooled unstimulated and stimulated human saliva (n= 5, duplicate).
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2.9. Statistical analysis
Results are expressed as mean ± standard deviation (SD).
Statistical differences between data sets were assessed using Kruskal-
Wallis with Dunn’s multiple comparisons test. A p value < 0.05 was
considered to represent a significant difference.
3. Results and discussion
3.1. Characterisation of pooled human saliva
The physicochemical parameters tested for pooled human saliva
were: pH, buffer capacity, viscosity, and surface tension (Fig. 2). All
physicochemical properties of saliva were comparable to saliva para-
meters measured for a wider population of healthy adult volunteers
(Gittings et al., 2015). This suggests that the pooling approach had not
significantly altered saliva characteristics and therefore was suitable to
use for biorelevant dissolution testing. Additional potential approaches
to take the use of pooled human saliva dissolution studies further would
be to characterise saliva within different age groups and disease states
that are applicable for the treatment/medication of interest.
3.2. Dissolution of felodipine powder in pooled stimulated human saliva
The concentrations of felodipine from various formulations after
pooled stimulated human saliva dissolution are shown in Figs. 3 and 4.
The initial dissolution testing of felodipine API powder demonstrates
that felodipine has a very low concentration post-dissolution within
pooled stimulated human saliva (34 ng/mL), which is 7-fold lower than
reported concentration in pH 7.4 buffer (Alelyunas et al., 2009), 100-
fold lower than the reported concentration in water (Kim et al., 2006;
Mielcarek et al., 2006), and 600-fold lower than reported for pH 6.8
buffer (Bhole and Patil, 2009). The low concentration of felodipine post
10-minute dissolution in pooled stimulated saliva demonstrates that
this compound and probably other drugs with similar physicochemical
properties would require solubility enhancement for successful buccal/
sublingual delivery.
In this study, the effect of three different solubility enhancement
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Fig. 3. The effect of dissolution enhancement strategies including cryomilling, addition of Soluplus®, and inclusion with beta-cyclodextrin (βCD) on the con-
centration of felodipine post 10-minute dissolution in pooled stimulated human saliva. Values are expressed as mean ± SD (n=3). Statistical analysis was per-
formed using Kruskal-Wallis with Dunn’s multiple comparisons test. Statistical differences compared to felodipine API and cryomilled felodipine without cyclo-
dextrins; *p < 0.05.
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strategies on the concentration of felodipine in pooled stimulated
human saliva was shown. Firstly, felodipine was cryomilled to enhance
dissolution by reducing particle size and by creating amorphous drug
particles. The next step was to add a polymeric solubilizer Soluplus®,
aiding the solubilisation of poorly soluble drugs in aqueous media. Next
was the inclusion of felodipine within cyclodextrins. Complexation with
cyclodextrins was achieved with two different methods, kneading and
lyophilisation. Figs. 3 and 4 show that significantly higher levels of
felodipine were observed using either βCD or MβCD, when coupled
with co-cryomilled felodipine and Soluplus® (Kruskal-Wallis with
Dunn’s multiple comparisons test). MβCD when complexed by the
kneading method or the lyophilisation (Lyo) method in the presence of
co-cryomilled felodipine and Soluplus® gave significantly higher con-
centrations of felodipine in stimulated saliva when compared to felo-
dipine API and cryomilled felodipine alone (Kruskal-Wallis with Dunn’s
multiple comparisons test). The use of these strategies separately did
not significantly increase drug concentration. Importantly it was found
that the combination of all three strategies: cryomilling, addition of
Soluplus®, and complexation with cyclodextrins gave a significant in-
crease in felodipine concentration in saliva (5.69 µg/mL for βCD,
10.41 µg/mL for MβCD) when compared to felodipine API powder.
Commercially available ODTs of other lipophilic compounds have
been produced primarily with the Zydis® technology, and one account
using the Quicksolv® technology (Fu et al., 2004). The Zydis® tech-
nology physically traps the drug within a water-soluble sugar/polymer
matrix which is then lyophilised. However, the use of lipophilic com-
pounds with Zydis® is not attributed to a direct increase in the water
solubility of the drug. Instead it is due to the fast disintegration times
associated with this technology, and the indirect benefit that com-
pounds that are practically insoluble in water will have less stability
issues due to moisture when compared to water soluble compounds
(Amipara and Gupta, 2013). This demonstrates that current commer-
cially available ODTs containing lipophilic compounds do not usually
employ drug solubility enhancement strategies such as those presented
in this study. However, there are previous reports of solid dispersions
and micronisation strategies for felodipine ODTs specifically
(Raghavendra Rao et al., 2010). Whilst there are several formulation
development procedures available to use in the development of ODTs
there are little to no biorelevant in vitro dissolution studies that can
determine the performance of ODTs within the oral cavity and therefore
guide rational design strategies.
3.3. Dissolution of felodipine orally disintegrating tablets (ODTs) in pooled
stimulated human saliva
Based on the results from the dissolution of different felodipine
powders (as described in Section 3.2) the inclusion of methyl-beta-cy-
clodextrin and co-milling with Soluplus® was utilised as the ODT for-
mulation. It was observed that 300mg ODTs with methyl-beta-cyclo-
dextrin with cryomilled felodipine, and cryomilled Soluplus®
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Fig. 4. The effect of dissolution enhancement strategies including cryomilling, addition of Soluplus®, and inclusion with methyl-beta-cyclodextrin (MβCD) on the
concentration of felodipine measured after 10-minute dissolution in pooled stimulated human saliva. Values are expressed as mean ± SD (n=3). Statistical analysis
was performed using Kruskal-Wallis with Dunn’s multiple comparisons test. Statistical differences compared to felodipine API and cryomilled felodipine without
cyclodextrins; *p < 0.05.
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significantly (p < 0.0001, Kruskal-Wallis with Dunn’s multiple com-
parisons test) increased the concentration of felodipine when compared
to felodipine 300mg tablets without cryomilling and without the ad-
dition of Soluplus®/cyclodextrins (Fig. 5).
3.4. Comparison between saliva-based dissolution and compendial
dissolution
Solid dosage forms are routinely evaluated within compendial dis-
solution apparatuses. For oral dosage forms, the compendial appara-
tuses used are USP 1–4. These dissolution apparatuses were designed
for conventional dosage forms (designed to be quickly swallowed) and
are capable of representing areas of the GI such as the stomach and
small intestine with appropriate selection of dissolution media (Culen
and Dohnal, 2013). However, the conventional dissolution set ups are
not suitable for oral cavity dissolution purposes, especially for orally
retained formulations such as ODTs for which their effectiveness is
primarily affected by the dissolution and solubility in mouth and saliva.
Percentage drug release was calculated at the 10min dissolution of
formulated felodipine ODTs in the stimulated saliva dissolution method
and in compendial USP 2 monograph dissolution. It was observed that
there is a significant difference in percentage drug release between
saliva-based dissolution, giving a 0.2% drug release, and compendial
dissolution, giving an 83% drug release from formulated ODTs (Fig. 6).
This study has shown that biorelevant pooled stimulated human
saliva dissolution allowed to guide the development of ODT formula-
tion of a model lipophilic compound and eventually to achieve over a
150-fold increase in concentration within saliva. Whilst this formula-
tion development has provided a substantial increase in felodipine
concentration, the percentage of felodipine released from ODTs in
pooled stimulated saliva still equates to only 0.2%. Interestingly, the
low drug release of felodipine in saliva in this oral cavity dissolution set
up is not reflected in compendial USP 2 dissolution of felodipine ODTs
and felodipine API. Compendial USP 2 dissolution resulted in felodipine
API release ranging from 30 to 40% as reported by others (Basalious
et al., 2013) and supported by our own data presented here, as well as
in our previous studies (Hameed, 2017). Furthermore, compendial USP
2 dissolution tests on formulated felodipine ODTs following production
as stated in this study resulted in 83% drug release after 10min
(Hameed, 2017). Another report has also shown that percentage release
of felodipine from ODTs was over 80% after 5min dissolution in
compendial USP 2 dissolution apparatus (Tung et al., 2014). The USP 2
dissolution studies for felodipine mentioned were all adapted from the
felodipine monograph designed for extended release tablets (United
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Fig. 5. The concentration of felodipine measured and percentage drug released after 10-minute dissolution of formulated tablets in pooled stimulated human saliva.
Values are expressed as mean ± SD (n=3). Statistical analysis was performed using Kruskal-Wallis with Dunn’s multiple comparisons test. Statistical differences
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States Pharmacopeia, 2009).
The felodipine monograph method (United States Pharmacopeia,
2009) recommends the use of phosphate buffer (pH 6.5) with 1% SLS as
dissolution media. It is likely that the large differences seen in per-
centage drug release between USP 2 dissolution and oral cavity dis-
solution is due to the differences between the two dissolution media
used. This highlights the benefit of using human saliva as dissolution
media to avoid the potentially skewed picture of predicted ODT per-
formance generated by standard compendial dissolution media ap-
proaches.
Further studies will be needed to assess if the proposed biorelevant
pooled saliva dissolution approach could to be used successfully for
rational development of wide range of compounds with poor aqueous
solubility.
4. Conclusion
In this study it has been found that biorelevant pooled stimulated
human saliva dissolution approach guided rational design of orally
disintegrating tablets of a model poorly water soluble compound, fe-
lodipine. With the use of cryomilling, solid dispersion, and inclusion
complexation strategies together as much as a 150-fold increase in
concentration of felodipine in human saliva was achieved. Whilst these
formulation strategies greatly increased felodipine concentration in
saliva, the percent of dose released was still very low (0.2%). The drug
release from the same formulation using a compenidal phosphate buffer
was shown to be as high as 83%. The discrepancy in drug release be-
tween dissolution media highlights the importance of dissolution ap-
paratus and biorelevant media selection for efficient assessment of
performance of orally retained formulations. Further studies will be
needed to assess if the proposed biorelevant pooled saliva dissolution
approach could be successfully used for rational development of wide
range of compounds with poor aqueous solubility.
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